GI Innovation is a bio-venture company that researches and develops innovative protein new drugs through well-structured translational research. The primary research and development for GI Innovation is immuno-oncology drug and allergy disease and developing a fusion protein using the GI-SMART™ platform. Currently, research and development is underway on subsequent pipelines such as non-alcoholic fatty hepatitis (NASH), following immuno-oncology drug and allergy treatments that continue to be researched and developed. We, GI Innovation, will do our best to advance treatments for patients with incurable diseases around the world.

GI-SMART™ : Expedited identification of protein candidates to accelerate clinical development SMART-cLego™ : Efficient generation of expression vector Bispecific fusion protein production technology SMART-Selex™ : Libraries for optimal fusion protein production High-throughput screening in selection process

Public

Biotech